News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zero Infections in High-Risk Cardiac Device Replacements Reported With Use of TYRX Antibacterial Envelope


6/26/2013 11:22:04 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ATHENS, Greece--(BUSINESS WIRE)--Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope reduced major infection rates by 100% in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to case-matched retrospective control patients. Investigators presented new interim results from the Citadel / Centurion Clinical Study today at the Late Breaking Clinical Trials session at the European Heart Rhythm Association (EHRA), EUROPACE 2013. The Citadel / Centurion study is a prospective, multicenter clinical study in patients at high-risk for CIED infection who have their CIED implanted with the AIGISRx Antibacterial Envelope. The aim of the study is to evaluate the impact of the AIGISRx Antibacterial Envelope on major device infection and mechanical complication rates in the 12-months after implantation. Investigators at 55 US centers enrolled patients who were at high-risk for device infection because they were undergoing a CIED replacement procedure with either an implantable cardioverter-defibrillator (ICD), (Citadel), or a cardiac resynchronization therapy (CRT) device (Centurion).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
TYRX
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES